Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 1/2024

Open Access 13-05-2023 | Prostate Cancer | REVIEW ARTICLE

Role of miR-424 in the carcinogenesis

Authors: Soudeh Ghafouri-Fard, Arian Askari, Bashdar Mahmud Hussen, Mohammad Taheri, Nader Akbari Dilmaghani

Published in: Clinical and Translational Oncology | Issue 1/2024

Login to get access

Abstract

Recent studies have revealed the impact of microRNAs (miRNAs) in the carcinogenic process. miR-424 is a miRNA whose role in this process is being to be identified. Experiments in the ovarian cancer, cervical cancer, hepatocellular carcinoma, neuroblastoma, breast cancer, osteosarcoma, intrahepatic cholangiocarcinoma, prostate cancer, endometrial cancer, non-small cell lung cancer, hemangioma and gastric cancer have reported down-regulation of miR-424. On the other hand, this miRNA has been found to be up-regulated in melanoma, laryngeal and esophageal squamous cell carcinomas, glioma, multiple myeloma and thyroid cancer. Expression of this miRNA is regulated by methylation status of its promoter. Besides, LINC00641, CCAT2, PVT1, LIN00657, LINC00511 and NNT-AS1 are among lncRNAs that act as molecular sponges for miR-424, thus regulating its expression. Moreover, several members of SNHG family of lncRNAs have been found to regulate expression of miR-424. This miRNA is also involved in the regulation of E2F transcription factors. The current review aims at summarization of the role of miR-424 in the process of cancer evolution and its impact on clinical outcome of patients in order to find appropriate markers for malignancies.
Literature
1.
2.
Hussen BM, Hidayat HJ, Salihi A, Sabir DK, Taheri M, Ghafouri-Fard S. MicroRNA: a signature for cancer progression. Biomed Pharmacother. 2021;138: 111528.PubMed
3.
Hussen BM, Abdullah ST, Rasul MF, Salihi A, Ghafouri-Fard S, Hidayat HJ, et al. MicroRNAs: important players in breast cancer angiogenesis and therapeutic targets. Front Mol Biosci. 2021;8: 764025.PubMedPubMedCentral
4.
Ghafouri-Fard S, Honarmand Tamizkar K, Hussen BM, Taheri M. MicroRNA signature in liver cancer. Pathology - Research and Practice. 2021;219: 153369.PubMed
5.
Ghafouri-Fard S, Hussen BM, Badrlou E, Abak A, Taheri M. MicroRNAs as important contributors in the pathogenesis of colorectal cancer. Biomed Pharmacother. 2021;140: 111759.PubMed
6.
Hussen BM, Hidayat HJ, Ghafouri-Fard S. Identification of expression of CCND1-related lncRNAs in breast cancer. Pathology - Research and Practice. 2022;236: 154009.PubMed
7.
Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004;14(10a):1902–10.PubMedPubMedCentral
8.
Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T. New microRNAs from mouse and human. RNA. 2003;9(2):175–9.PubMedPubMedCentral
9.
Wan MF, Yang N, Qu NY, Pan YY, Shan YQ, Li P. MiR-424 suppressed viability and invasion by targeting to the DCLK1 in neuroblastoma. Eur Rev Med Pharmacol Sci. 2020;24(10):5526–33.PubMed
10.
Vimalraj S, Saravanan S, Raghunandhakumar S, Anuradha D. Melatonin regulates tumor angiogenesis via miR-424-5p/VEGFA signaling pathway in osteosarcoma. Life Sci. 2020;256: 118011.PubMed
11.
Gheidari F, Arefian E, Adegani FJ, Kalhori MR, Seyedjafari E, Kabiri M, et al. miR-424 induces apoptosis in glioblastoma cells and targets AKT1 and RAF1 oncogenes from the ERBB signaling pathway. Eur J Pharmacol. 2021;906: 174273.PubMed
12.
Dai W, Zhou J, Wang H, Zhang M, Yang X, Song W. miR-424-5p promotes the proliferation and metastasis of colorectal cancer by directly targeting SCN4B. Pathol Res Pract. 2020;216(1): 152731.PubMed
13.
Li Y, Liu J, Hu W, Zhang Y, Sang J, Li H, et al. miR-424-5p promotes proliferation, migration and invasion of laryngeal squamous cell carcinoma. Onco Targets Ther. 2019;12:10441–53.PubMedPubMedCentral
14.
Zhang M, Zeng J, Zhao Z, Liu Z. Loss of MiR-424-3p, not miR-424-5p, confers chemoresistance through targeting YAP1 in non-small cell lung cancer. Mol Carcinog. 2017;56(3):821–32.PubMed
15.
Zimta AA, Tigu AB, Braicu C, Stefan C, Ionescu C, Berindan-Neagoe I. An emerging class of long non-coding RNA with oncogenic role arises from the snoRNA host genes. Front Oncol. 2020;10:389.PubMedPubMedCentral
16.
Li Z, Wang X, Liang S. Long non-coding RNA small nucleolar RNA host gene 1 knockdown suppresses the proliferation, migration and invasion of osteosarcoma cells by regulating microRNA-424-5p/FGF2 in vitro. Exp Ther Med. 2021;21(4):325.PubMedPubMedCentral
17.
Dong J, Wang Q, Li L, Xiao-Jin Z. Upregulation of long non-coding RNA small nucleolar RNA host gene 12 contributes to cell growth and invasion in cervical cancer by acting as a sponge for MiR-424-5p. Cell Physiol Biochem. 2018;45(5):2086–94.PubMed
18.
Liu R, Wu M, Xu G, Ju L, Xiao J, Zhong W, et al. Ropivacaine inhibits proliferation, migration, and invasion while inducing apoptosis of glioma cells by regulating the SNHG16/miR-424-5p axis. Open Life Sci. 2020;15(1):988–99.PubMedPubMedCentral
19.
Yee AS, Reichel R, Kovesdi I, Nevins JR. Promoter interaction of the E1A-inducible factor E2F and its potential role in the formation of a multi-component complex. Embo j. 1987;6(7):2061–8.PubMedPubMedCentral
20.
21.
Zhao Y, Zhu C, Chang Q, Peng P, Yang J, Liu C, et al. MiR-424-5p regulates cell cycle and inhibits proliferation of hepatocellular carcinoma cells by targeting E2F7. PLoS One. 2020;15(11): e0242179.PubMedPubMedCentral
22.
Yang H, Zheng W, Shuai X, Chang RM, Yu L, Fang F, et al. MicroRNA-424 inhibits Akt3/E2F3 axis and tumor growth in hepatocellular carcinoma. Oncotarget. 2015;6(29):27736–50.PubMedPubMedCentral
23.
Lu Z, Nian Z, Jingjing Z, Tao L, Quan L. MicroRNA-424/E2F6 feedback loop modulates cell invasion, migration and EMT in endometrial carcinoma. Oncotarget. 2017;8(69):114281–91.PubMedPubMedCentral
24.
Li Q, Qiu XM, Li QH, Wang XY, Li L, Xu M, et al. MicroRNA-424 may function as a tumor suppressor in endometrial carcinoma cells by targeting E2F7. Oncol Rep. 2015;33(5):2354–60.PubMed
25.
Li H, Lan H, Zhang M, An N, Yu R, He Y, et al. Effects of miR-424 on proliferation and migration abilities in non-small cell lung cancer A549 cells and its molecular mechanism. Zhongguo Fei Ai Za Zhi. 2016;19(9):571–6.PubMed
26.
27.
Zhou K, Li S, Du G, Fan Y, Wu P, Sun H, et al. LncRNA XIST depletion prevents cancer progression in invasive pituitary neuroendocrine tumor by inhibiting bFGF via upregulation of microRNA-424-5p. Onco Targets Ther. 2019;12:7095–109.PubMedPubMedCentral
28.
Ning D, Chen J, Du P, Liu Q, Cheng Q, Li X, et al. The crosstalk network of XIST/miR-424-5p/OGT mediates RAF1 glycosylation and participates in the progression of liver cancer. Liver Int. 2021;41(8):1933–44.PubMed
29.
Dai Y, Zhu Y, Xu H. circ_0004872 inhibits proliferation, invasion, and glycolysis of oral squamous cell carcinoma by sponged miR-424-5p. J Clin Lab Anal. 2022;36(7): e24486.PubMedPubMedCentral
30.
Zhang Y, Tang K, Chen L, Du M, Qu Z. Exosomal CircGDI2 suppresses oral squamous cell carcinoma progression through the regulation of MiR-424-5p/SCAI axis. Cancer Manag Res. 2020;12:7501–14.PubMedPubMedCentral
31.
Liu Y, Wang G, Li Y, Zhao Q, Fan L, Tan B, et al. miR-424-5p reduces 5-fluorouracil resistance possibly by inhibiting Src/focal adhesion kinase signalling-mediated epithelial-mesenchymal transition in colon cancer cells. J Pharm Pharmacol. 2021;73(8):1062–70.PubMed
32.
Fang Y, Liang X, Xu J, Cai X. miR-424 targets AKT3 and PSAT1 and has a tumor-suppressive role in human colorectal cancer. Cancer Manag Res. 2018;10:6537–47.PubMedPubMedCentral
33.
Zhang N, Li L, Luo J, Tan J, Hu W, Li Z, et al. Inhibiting microRNA-424 in bone marrow mesenchymal stem cells-derived exosomes suppresses tumor growth in colorectal cancer by upregulating TGFBR3. Arch Biochem Biophys. 2021;709: 108965.PubMed
34.
Li N. CircTBL1XR1/miR-424 axis regulates Smad7 to promote the proliferation and metastasis of colorectal cancer. J Gastrointest Oncol. 2020;11(5):918–31.PubMedPubMedCentral
35.
Yan W, Jiang X, Wang G, Li W, Zhai C, Chen S, et al. Cyto-biological effects of microRNA-424-5p on human colorectal cancer cells. Oncol Lett. 2020;20(4):120.PubMedPubMedCentral
36.
Cheng C, Li H, Zheng J, Xu J, Gao P, Wang J. FENDRR sponges miR-424-5p to inhibit cell proliferation, migration and invasion in colorectal cancer. Technol Cancer Res Treat. 2020;19:1533033820980102.PubMedPubMedCentral
37.
Shekhar R, Priyanka P, Kumar P, Ghosh T, Khan MM, Nagarajan P, et al. The microRNAs miR-449a and miR-424 suppress osteosarcoma by targeting cyclin A2 expression. J Biol Chem. 2019;294(12):4381–400.PubMedPubMedCentral
38.
Hu Y, Gu J, Shen H, Shao T, Li S, Wang W, et al. Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma. J Clin Lab Anal. 2020;34(2): e23045.PubMed
39.
Long XH, Mao JH, Peng AF, Zhou Y, Huang SH, Liu ZL. Tumor suppressive microRNA-424 inhibits osteosarcoma cell migration and invasion via targeting fatty acid synthase. Exp Ther Med. 2013;5(4):1048–52.PubMedPubMedCentral
40.
Li R, Ruan Q, Zheng J, Zhang B, Yang H. LINC01116 promotes doxorubicin resistance in osteosarcoma by epigenetically silencing miR-424-5p and inducing epithelial-mesenchymal transition. Front Pharmacol. 2021;12: 632206.PubMedPubMedCentral
41.
42.
Han X, Jia Y, Chen X, Sun C, Sun J. lncRNA TINCR attenuates the proliferation and invasion, and enhances the apoptosis of cutaneous malignant melanoma cells by regulating the miR-424-5p/LATS1 axis. Oncol Rep. 2021;46(5):1–11.
43.
Zhou Y, Yamamoto Y, Takeshita F, Yamamoto T, Xiao Z, Ochiya T. Delivery of miR-424-5p via extracellular vesicles promotes the apoptosis of MDA-MB-231 TNBC cells in the tumor microenvironment. Int J Mol Sci. 2021;22(2):844.PubMedPubMedCentral
44.
Dastmalchi N, Safaralizadeh R, Hosseinpourfeizi MA, Baradaran B, Khojasteh SMB. MicroRNA-424-5p enhances chemosensitivity of breast cancer cells to Taxol and regulates cell cycle, apoptosis, and proliferation. Mol Biol Rep. 2021;48(2):1345–57.PubMed
45.
Kim H, Ji HW, Kim HW, Yun SH, Park JE, Kim SJ. Ginsenoside Rg3 prevents oncogenic long noncoding RNA ATXN8OS from inhibiting tumor-suppressive microRNA-424-5p in breast cancer cells. Biomolecules. 2021;11(1):118.PubMedPubMedCentral
46.
Xie D, Song H, Wu T, Li D, Hua K, Xu H, et al. MicroRNA-424 serves an anti-oncogenic role by targeting cyclin-dependent kinase 1 in breast cancer cells. Oncol Rep. 2018;40(6):3416–26.PubMedPubMedCentral
47.
48.
Dastmalchi N, Safaralizadeh R, Khojasteh SMB, Shadbad MA, Hosseinpourfeizi MA, Azarbarzin S, et al. The combined restoration of miR-424-5p and miR-142-3p effectively inhibits MCF-7 breast cancer cell line via modulating apoptosis, proliferation, colony formation, cell cycle and autophagy. Mol Biol Rep. 2022;49(9):8325–35.PubMed
49.
Wang J, Wang S, Zhou J, Qian Q. miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer. Biomed Pharmacother. 2018;102:147–52.PubMed
50.
Chen B, Duan L, Yin G, Tan J, Jiang X. Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells–-Cdc2 activity is up-regulated by targeting WEE1. Clinics (Sao Paulo). 2013;68(6):825–33.PubMed
51.
Li D, Liu K, Li Z, Wang J, Wang X. miR-19a and miR-424 target TGFBR3 to promote epithelial-to-mesenchymal transition and migration of tongue squamous cell carcinoma cells. Cell Adh Migr. 2018;12(3):236–46.PubMed
52.
Li Y, Liu H, Cui Y, Chen H, Cui X, Shao J, et al. miR-424-3p contributes to the malignant progression and chemoresistance of gastric cancer. Onco Targets Ther. 2020;13:12201–11.PubMedPubMedCentral
53.
Wei S, Li Q, Li Z, Wang L, Zhang L, Xu Z. miR-424-5p promotes proliferation of gastric cancer by targeting Smad3 through TGF-β signaling pathway. Oncotarget. 2016;7(46):75185–96.PubMedPubMedCentral
54.
Su J, Chen D, Ruan Y, Tian Y, Lv K, Zhou X, et al. LncRNA MBNL1-AS1 represses gastric cancer progression via the TGF-β pathway by modulating miR-424-5p/Smad7 axis. Bioengineered. 2022;13(3):6978–95.PubMedPubMedCentral
55.
Zhang J, Liu H, Hou L, Wang G, Zhang R, Huang Y, et al. Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. Mol Cancer. 2017;16(1):151.PubMedPubMedCentral
56.
Cui Y, Yang J, Bai Y, Zhang Y, Yao Y, Zheng T, et al. miR-424-5p regulates cell proliferation and migration of esophageal squamous cell carcinoma by targeting SIRT4. J Cancer. 2020;11(21):6337–47.PubMedPubMedCentral
57.
Wang F, Wang J, Yang X, Chen D, Wang L. MiR-424-5p participates in esophageal squamous cell carcinoma invasion and metastasis via SMAD7 pathway mediated EMT. Diagn Pathol. 2016;11(1):88.PubMedPubMedCentral
58.
Sun YP, Lu F, Han XY, Ji M, Zhou Y, Zhang AM, et al. MiR-424 and miR-27a increase TRAIL sensitivity of acute myeloid leukemia by targeting PLAG1. Oncotarget. 2016;7(18):25276–90.PubMedPubMedCentral
59.
Dallavalle C, Albino D, Civenni G, Merulla J, Ostano P, Mello-Grand M, et al. MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression. J Clin Invest. 2016;126(12):4585–602.PubMedPubMedCentral
60.
Wu ZB, Shi SL, Pan FJ, Li L, Chen HY. Propranolol inhibits infantile hemangioma by regulating the miR-424/vascular endothelial growth factor-A (VEGFA) axis. Transl Pediatr. 2021;10(7):1867–76.PubMedPubMedCentral
61.
Chen Y, Li B, Feng J, Fang Q, Cheng J, Xie W, et al. JAG1, Regulated by microRNA-424-3p, involved in tumorigenesis and epithelial-mesenchymal transition of high proliferative potential-pituitary adenomas. Front Oncol. 2020;10: 567021.PubMedPubMedCentral
62.
Liu J, Zhao H, Zhang Q, Shi Z, Zhang Y, Zhao L, et al. Human papillomavirus type 16 E7 oncoprotein-induced upregulation of lysine-specific demethylase 5A promotes cervical cancer progression by regulating the microRNA-424-5p/suppressor of zeste 12 pathway. Exp Cell Res. 2020;396(1): 112277.PubMed
63.
Wang Z, Jiao P, Zhong Y, Ji H, Zhang Y, Song H, et al. The endoplasmic reticulum-stressed head and neck squamous cell carcinoma cells induced exosomal miR-424-5p inhibits angiogenesis and migration of humanumbilical vein endothelial cells through LAMC1-mediated Wnt/β-catenin signaling pathway. Cell Transplant. 2022;31:9636897221083548.PubMed
64.
Lv HC, Lv YY, Wang G, Zhang XH, Li SN, Yue XF, et al. Mechanism of miR-424-5p promoter methylation in promoting epithelial-mesenchymal transition of hepatocellular carcinoma cells. Kaohsiung J Med Sci. 2022;38(4):336–46.PubMed
65.
Zhao Z, Huang W, He J, Feng C. MicroRNA-424 inhibits autophagy and proliferation of hepatocellular carcinoma cells by targeting ATG14. Nan Fang Yi Ke Da Xue Xue Bao. 2021;41(7):1012–21.PubMed
66.
Wu L, Yang F, Lin B, Chen X, Yin S, Zhang F, et al. MicroRNA-424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation. Oncol Lett. 2018;15(6):9126–32.PubMedPubMedCentral
67.
Zhao Z, He J, Feng C. CircCBFB is a mediator of hepatocellular carcinoma cell autophagy and proliferation through miR-424-5p/ATG14 axis. Immunol Res. 2022;70(3):341–53.PubMed
68.
Shen X, Li Y, He F, Kong J. LncRNA CDKN2B-AS1 promotes cell viability, migration, and invasion of hepatocellular carcinoma via sponging miR-424-5p. Cancer Manag Res. 2020;12:6807–19.PubMedPubMedCentral
69.
Du H, Xu Q, Xiao S, Wu Z, Gong J, Liu C, et al. MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29. Life Sci. 2019;224:1–11.PubMed
70.
Ye Z, He Q, Wang Q, Lin Y, Cen K, Chen X. LINC00922 promotes the proliferation, migration, invasion and EMT process of liver cancer cells by regulating miR-424-5p/ARK5. Mol Cell Biochem. 2021;476(10):3757–69.PubMed
71.
Wu L, Zhu X, Song Z, Chen D, Guo M, Liang J, et al. Long non-coding RNA HOXA-AS2 enhances the malignant biological behaviors in Glioma by epigenetically regulating RND3 expression. Onco Targets Ther. 2019;12:9407.PubMedPubMedCentral
72.
Lu M, Qin X, Zhou Y, Li G, Liu Z, Geng X, et al. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis. Cell Death Dis. 2021;12(1):72.PubMedPubMedCentral
73.
Wu J, Yang B, Zhang Y, Feng X, He B, Xie H, et al. miR-424-5p represses the metastasis and invasion of intrahepatic cholangiocarcinoma by targeting ARK5. Int J Biol Sci. 2019;15(8):1591–9.PubMedPubMedCentral
74.
Wu CT, Lin WY, Chang YH, Lin PY, Chen WC, Chen MF. DNMT1-dependent suppression of microRNA424 regulates tumor progression in human bladder cancer. Oncotarget. 2015;6(27):24119–31.PubMedPubMedCentral
75.
Li WJ, Li G, Liu ZW, Chen ZY, Pu R. LncRNA LINC00355 promotes EMT and metastasis of bladder cancer cells through the miR-424-5p/HMGA2 axis. Neoplasma. 2021;68(6):1225–35.PubMed
76.
Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. miR-34a, miR-424 and miR-513 inhibit MMSET expression to repress endometrial cancer cell invasion and sphere formation. Oncotarget. 2018;9(33):23253–63.PubMedPubMedCentral
77.
78.
Wang P, Liu T, Zhao Z, Wang Z, Liu S, Yang X. SPTBN2 regulated by miR-424-5p promotes endometrial cancer progression via CLDN4/PI3K/AKT axis. Cell Death Discov. 2021;7(1):382.PubMedPubMedCentral
79.
Bieg D, Sypniewski D, Nowak E, Bednarek I. MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Arch Gynecol Obstet. 2019;299(4):1077–87.PubMed
80.
Cho JG, Kim SW, Lee A, Jeong HN, Yun E, Choi J, et al. MicroRNA-dependent inhibition of WEE1 controls cancer stem-like characteristics and malignant behavior in ovarian cancer. Mol Ther Nucleic Acids. 2022;29:803–22.PubMedPubMedCentral
81.
Li P, Xin H, Lu L. Extracellular vesicle-encapsulated microRNA-424 exerts inhibitory function in ovarian cancer by targeting MYB. J Transl Med. 2021;19(1):4.PubMedPubMedCentral
82.
Liu J, Gu Z, Tang Y, Hao J, Zhang C, Yang X. Tumour-suppressive microRNA-424-5p directly targets CCNE1 as potential prognostic markers in epithelial ovarian cancer. Cell Cycle. 2018;17(3):309–18.PubMedPubMedCentral
83.
Ma LL, Liang L, Zhou D, Wang SW. Tumor suppressor miR-424-5p abrogates ferroptosis in ovarian cancer through targeting ACSL4. Neoplasma. 2021;68(1):165–73.PubMed
84.
Wu X, Ruan Y, Jiang H, Xu C. MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma. Int J Biochem Cell Biol. 2017;85:66–74.PubMed
85.
Wu K, Hu G, He X, Zhou P, Li J, He B, et al. MicroRNA-424-5p suppresses the expression of SOCS6 in pancreatic cancer. Pathol Oncol Res. 2013;19(4):739–48.PubMed
86.
Sun SL, Shu YG, Tao MY. LncRNA CCAT2 promotes angiogenesis in glioma through activation of VEGFA signalling by sponging miR-424. Mol Cell Biochem. 2020;468(1–2):69–82.PubMed
87.
Wang L, Adiga A, Venkatramanan S, Chen J, Lewis B, Marathe M. Examining deep learning models with multiple data sources for COVID-19 forecasting. In: 2020 IEEE international conference on big data (big data), Atlanta, GA, USA. IEEE; 2020. p. 3846–3855.
88.
Zhao C, Wang XB, Zhang YH, Zhou YM, Yin Q, Yao WC. MicroRNA-424 inhibits cell migration, invasion and epithelial-mesenchymal transition in human glioma by targeting KIF23 and functions as a novel prognostic predictor. Eur Rev Med Pharmacol Sci. 2018;22(19):6369–78.PubMed
89.
Xu H, Zhang H, Tan L, Yang Y, Wang H, Zhao Q, et al. FAM87A as a competing endogenous RNA of miR-424-5p suppresses glioma progression by regulating PPM1H. Comput Math Methods Med. 2021;2021:7952922.PubMedPubMedCentral
90.
Zhao C, Zhao F, Chen H, Liu Y, Su J. MicroRNA-424-5p inhibits the proliferation, migration, and invasion of nasopharyngeal carcinoma cells by decreasing AKT3 expression. Braz J Med Biol Res. 2020;53(7): e9029.PubMedPubMedCentral
91.
Lu C, Wang H, Chen S, Yang R, Li H, Zhang G. Baicalein inhibits cell growth and increases cisplatin sensitivity of A549 and H460 cells via miR-424-3p and targeting PTEN/PI3K/Akt pathway. J Cell Mol Med. 2018;22(4):2478–87.PubMedPubMedCentral
92.
Wang Y, Lv Z, Fu J, Wang Z, Fan Z, Lei T. Endogenous microRNA-424 predicts clinical outcome and its inhibition acts as cancer suppressor in human non-small cell lung cancer. Biomed Pharmacother. 2017;89:208–14.PubMed
93.
Wen J, Hu Y, Liu Q, Ling Y, Zhang S, Luo K, et al. miR-424 coordinates multilayered regulation of cell cycle progression to promote esophageal squamous cell carcinoma cell proliferation. EBioMedicine. 2018;37:110–24.PubMedPubMedCentral
94.
Liu X, Fu Y, Zhang G, Zhang D, Liang N, Li F, et al. miR-424-5p promotes anoikis resistance and lung metastasis by inactivating hippo signaling in thyroid cancer. Mol Ther Oncolytics. 2019;15:248–60.PubMedPubMedCentral
95.
Xu J, Li Y, Wang F, Wang X, Cheng B, Ye F, et al. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene. 2013;32(8):976–87.PubMed
96.
Hua F, Li CH, Chen XG, Liu XP. Long noncoding RNA CCAT2 knockdown suppresses tumorous progression by sponging miR-424 in epithelial ovarian cancer. Oncol Res. 2018;26(2):241–7.PubMedPubMedCentral
97.
Bolandparva F, Hashemi Nasab MS, Mohamadnia A, Garajei A, Farhadi Nasab A, Bahrami N. Early diagnosis of oral squamous cell carcinoma (OSCC) by miR-138 and miR-424-5p expression as a cancer marker. Asian Pac J Cancer Prev. 2021;22(7):2185–9.PubMedPubMedCentral
98.
Chen B, Zhao Q, Guan L, Lv H, Bie L, Huang J, et al. Long non-coding RNA NNT-AS1 sponges miR-424/E2F1 to promote the tumorigenesis and cell cycle progression of gastric cancer. J Cell Mol Med. 2018;22(10):4751–9.PubMedPubMedCentral
99.
Gao YL, Zhao ZS, Zhang MY, Han LJ, Dong YJ, Xu B. Long noncoding RNA PVT1 facilitates cervical cancer progression via negative regulating of miR-424. Oncol Res. 2017;25(8):1391–8.PubMedPubMedCentral
100.
Teng F, Zhang JX, Chang QM, Wu XB, Tang WG, Wang JF, et al. LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39(1):235.PubMedPubMedCentral
101.
Cao X, Zhang G, Li T, Zhou C, Bai L, Zhao J, et al. LINC00657 knockdown suppresses hepatocellular carcinoma progression by sponging miR-424 to regulate PD-L1 expression. Genes Genomics. 2020;42(11):1361–8.PubMed
102.
Wang RP, Jiang J, Jiang T, Wang Y, Chen LX. Increased long noncoding RNA LINC00511 is correlated with poor prognosis and contributes to cell proliferation and metastasis by modulating miR-424 in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2019;23(8):3291–301.PubMed
103.
Yao J, Fu J, Liu Y, Qu W, Wang G, Yan Z. LncRNA CASC9 promotes proliferation, migration and inhibits apoptosis of hepatocellular carcinoma cells by down-regulating miR-424-5p. Ann Hepatol. 2021;23: 100297.PubMed
104.
105.
Rodriguez-Barrueco R, Nekritz EA, Bertucci F, Yu J, Sanchez-Garcia F, Zeleke TZ, et al. miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev. 2017;31(6):553–66.PubMedPubMedCentral
106.
Liu Z, Huang S, Lu W, Su Z, Yin X, Liang H, et al. Modeling the trend of coronavirus disease 2019 and restoration of operational capability of metropolitan medical service in China: a machine learning and mathematical model-based analysis. Glob Health Res Policy. 2020;5:20.PubMedPubMedCentral
107.
Scholtz B, Horváth J, Tar I, Kiss C, Márton IJ. Salivary miR-31-5p, miR-345-3p, and miR-424-3p are reliable biomarkers in patients with oral squamous cell carcinoma. Pathogens. 2022;11(2):229.PubMedPubMedCentral
108.
Richardsen E, Andersen S, Al-Saad S, Rakaee M, Nordby Y, Pedersen MI, et al. Low expression of miR-424-3p is highly correlated with clinical failure in prostate cancer. Sci Rep. 2019;9(1):10662. PubMedPubMedCentral
109.
Nakashima T, Jinnin M, Etoh T, Fukushima S, Masuguchi S, Maruo K, et al. Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy. PLoS ONE. 2010;5(12): e14334.PubMedPubMedCentral
110.
Li MM, Dong CX, Sun B, Lei HZ, Wang YL, Gong YB, et al. LncRNA-MALAT1 promotes tumorogenesis of infantile hemangioma by competitively binding miR-424 to stimulate MEKK3/NF-κB pathway. Life Sci. 2019;239: 116946.PubMed
111.
Huang JJ, Zhuo F, Cai YH, Xiao H. Expression and clinical significance of serum MiR-424 and MiR-765 in multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022;30(2):461–5.PubMed
112.
113.
Lyu J, Zhao L, Wang F, Ji J, Cao Z, Xu H, et al. Discovery and validation of serum MicroRNAs as early diagnostic biomarkers for prostate cancer in Chinese population. Biomed Res Int. 2019;2019:9306803.PubMedPubMedCentral
114.
Xiao CT, Lai WJ, Zhu WA, Wang H. MicroRNA derived from circulating exosomes as noninvasive biomarkers for diagnosing renal cell carcinoma. Onco Targets Ther. 2020;13:10765–74.PubMedPubMedCentral
115.
Li Y, Zhao L, Zhao P, Liu Z. Long non-coding RNA LINC00641 suppresses non-small-cell lung cancer by sponging miR-424-5p to upregulate PLSCR4. Cancer Biomark. 2019;26(1):79–91.PubMed
116.
Ding J, Zhang L, Chen S, Cao H, Xu C, Wang X. lncRNA CCAT2 enhanced resistance of glioma cells against chemodrugs by disturbing the normal function of miR-424. OncoTargets and Ther. 2020;13:1431–45.
117.
Han Y, Li X, Yan J, Ma C, Zheng X, Zhang J, et al. Knockdown of lncRNA PVT1 inhibits glioma progression by regulating miR-424 expression. Oncol Res Featur Preclin Clin Cancer Ther. 2019;27(6):681–90.
118.
Huang Y-A, Huang Z-A, You Z-H, Zhu Z, Huang W-Z, Guo J-X, et al. Predicting lncRNA-miRNA interaction via graph convolution auto-encoder. Front Genet. 2019;10:758.PubMedPubMedCentral
119.
Ghonbalani ZN, Shahmohamadnejad S, Pasalar P, Khalili E. Hypermethylated miR-424 in colorectal cancer subsequently upregulates VEGF. J Gastrointest Cancer. 2022;53(2):380–6.PubMed
120.
Zhu B, Ju S, Chu H, Shen X, Zhang Y, Luo X, et al. The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma. Oncol Lett. 2018;15(5):6094–106.PubMedPubMedCentral
121.
Kanwal R, Plaga AR, Liu X, Shukla GC, Gupta S. MicroRNAs in prostate cancer: functional role as biomarkers. Cancer Lett. 2017;407:9–20.PubMed
122.
Hanna J, Hossain GS, Kocerha J. The potential for microRNA therapeutics and clinical research. Front Genet. 2019;10:478.PubMedPubMedCentral
123.
Metadata
Title
Role of miR-424 in the carcinogenesis
Authors
Soudeh Ghafouri-Fard
Arian Askari
Bashdar Mahmud Hussen
Mohammad Taheri
Nader Akbari Dilmaghani
Publication date
13-05-2023

Other articles of this Issue 1/2024

Clinical and Translational Oncology 1/2024 Go to the issue

RESEARCH ARTICLE

Comparative analysis of upper aerodigestive tract and non-upper aerodigestive tract in NK/T-cell lymphoma

RESEARCH ARTICLE

Diagnosis of SPECT/CT bone imaging combined with two serum examinations in patients with bone metastases from pulmonary cancer

RESEARCH ARTICLE

NPHS2-6 drives cervical squamous cell carcinoma (CSCC) progression via hsa-miR-1323/SMC1B axis to activate PI3K-Akt pathway

RESEARCH ARTICLE

The expression of corticotropin-releasing hormone family peptides in premalignant and malignant vulvar lesions

RESEARCH ARTICLE

Frequency of anticancer drug use at the end of life: a scoping review

RESEARCH ARTICLE

Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits